Compare PBH & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | AUPH |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2004 | 2014 |
| Metric | PBH | AUPH |
|---|---|---|
| Price | $42.87 | $16.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $67.80 | $18.29 |
| AVG Volume (30 Days) | 512.0K | ★ 862.5K |
| Earning Date | 11-05-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | 0.76 |
| Revenue | ★ $975,777,000.00 | $283,055,000.00 |
| Revenue This Year | $19.22 | $16.65 |
| Revenue Next Year | $6.35 | $17.73 |
| P/E Ratio | $46.74 | ★ $22.51 |
| Revenue Growth | ★ 36.77 | N/A |
| 52 Week Low | $42.62 | $13.52 |
| 52 Week High | $71.07 | $19.25 |
| Indicator | PBH | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 47.46 |
| Support Level | N/A | $15.61 |
| Resistance Level | $50.26 | $16.48 |
| Average True Range (ATR) | 1.95 | 0.55 |
| MACD | -0.38 | -0.08 |
| Stochastic Oscillator | 15.39 | 28.13 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.